CD66B, CD66C AND CARCINOEMBRYONIC ANTIGEN (CEA) ARE INDEPENDENTLY REGULATED MARKERS IN SERA OF TUMOR PATIENTS
CD66B, CD66C AND CARCINOEMBRYONIC ANTIGEN (CEA) ARE INDEPENDENTLY REGULATED MARKERS IN SERA OF TUMOR PATIENTS
复制标题
DOI：
10.1002/ijc.2910630308
复制
发表时间：
1995-11-03
影响因子：
6.4
通讯作者：
JANTSCHEFF, P
中科院分区：
文献类型：
--
作者：
GRUNERT, F;DANIEL, S;JANTSCHEFF, P
非特异性交叉反应抗原（NCA-95 = CD 66 b和NCA-50/90 = CD 66 c）是CEA（癌胚抗原= CD 66 e）家族的成员。结肠肿瘤中CD 66 c的mRNA水平的分析表明，该抗原与其正常对应物相比强烈上调，因此可能具有临床意义。CD 66 c也在正常肺和脾组织中表达，尤其是在粒细胞上。CD 66 b是唯一严格的粒细胞特异性抗原，其在血清中的出现可能表明粒细胞参与了疾病。建立了特异性夹心ELISA法测定血清CEA、CD 66 b和CD 66 c水平。已通过测试来自良性肿瘤或炎性疾病患者和健康个体的血清来进行对照。在大多数患有实体瘤的患者的血清中，CD 66 c的敏感性与CEA的敏感性相当或低于CEA的敏感性。CD 66 c在早期结肠肿瘤分期中显示出更高的敏感性。在子宫癌和肾癌患者的血清中，已确定了超过40%的灵敏度为CD 66 b。CML患者对CD 66 c的敏感性为84%，对CD 66 b的敏感性为47%。对CEA阴性的炎性结肠疾病患者的血清的研究显示出对CD 66 c的高敏感性，但对粒细胞特异性CD 66 b的敏感性不高。乳腺病患者对CD 66 c和CD 66 b的敏感性均超过40%。CD 66 b、CD 66 c和CEA在高百分比的患者中是独立调节的蛋白质。CEA和CD 66 b/c联合检测可提高对恶性肿瘤的敏感性，但CD 66 b/c对良性疾病的高敏感性限制了它们作为肿瘤标志物的应用。CD 66 b可能是一个有趣的肾癌和体癌的标志物，好的标志物还没有。(C)1995 Wiley-Liss，Inc.
Non-specific cross-reacting antigens (NCA-95 = CD66b and NCA-50/90 = CD66c) are members of the CEA (carcinoembryonic antigen = CD66e) family. Analysis of mRNA levels of CD66c in colon tumors suggests that this antigen is strongly up-regulated compared to its normal counterpart and could, therefore, be of clinical interest. CD66c is also expressed in normal lung and spleen tissues and, above all, on granulocytes. The appearance of CD66b in serum, the only strictly granulocyte-specific antigen, could point to the involvement of granulocytes in disease. Specific sandwich ELISAs have been established to determine CEA, CD66b and CD66c levels in serum. Controls have been carried out by testing sera from patients with benign tumors or inflammatory diseases and from healthy individuals. In sera of most patients suffering from solid tumors, sensitivities for CD66c are comparable to or lower than those for CEA. CD66c showed a much higher sensitivity in early colon tumor stages. Sensitivities over 40% have been determined for CD66b in sera of patients with uterine and kidney carcinomas. CML patients revealed sensitivities of 84% for CD66c and 47% for CD66b. investigations of sera from patients with inflammatory colon diseases which are negative for CEA showed high sensitivity for CD66c but not for the granulocyte-specific CD66b. Patients with mastopathy revealed sensitivities of over 40% for both CD66c and CD66b. CD66b, CD66c and CEA are independently regulated proteins in a high percentage of patients. The simultaneous determination of CEA and CD66b/c can increase the sensitivities for malignant tumors but high sensitivities of CD66b/c for benign diseases limit their usefulness as tumor markers. CD66b may be interesting as a marker for kidney and corpus carcinomas, for which good markers are not yet available. (C) 1995 Wiley-Liss, Inc.